NasdaqCM - Delayed Quote ? USD Profound Medical Corp. (PROF) Follow Compare 7.84 -0.17 (-2.12%) At close: November 18 at 4:00 PM EST All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Profound Medical to Participate in the Stifel 2024 Healthcare Conference TORONTO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the Company’s business at the Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024 at 9:45 a.m. Eastern Time in NYC. The presentation will be broadcast live and archive GlobeNewswire ? 6 days ago PROF -2.12% Profound Medical Third Quarter 2024 Earnings: Misses Expectations Profound Medical ( TSE:PRN ) Third Quarter 2024 Results Key Financial Results Net loss: US$9.36m (loss widened by 68... Simply Wall St. ? 9 days ago PROF -2.12% Profound Medical Corp (PROF) Q3 2024 Earnings Call Highlights: Revenue Surge Amidst Rising Expenses Profound Medical Corp (PROF) reports a 64% revenue increase in Q3 2024, but faces challenges with increased operating expenses and a significant net loss. GuruFocus.com ? 10 days ago PROF -2.12% Profound Medical Announces Third Quarter 2024 Financial Results TORONTO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the third quarter ended September 30, 2024. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with International Financial Rep GlobeNewswire ? 11 days ago PROF -2.12% Profound Medical Announces TULSA Reimbursement Raised to Urology APC Level 7 Under CMS Outpatient Prospective Payment System (OPPS) Final Rule for CY2025 – TULSA to stand above all other covered prostate disease treatment modalities at Urology Level 7 reimbursement – – First-time CPT? code reimbursement for TULSA to be effective January 1, 2025 – TORONTO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that U.S. Centers for Medi GlobeNewswire ? 14 days ago PROF -2.12% Profound Medical to Release Third Quarter 2024 Financial Results on November 7 – Conference Call to Follow TORONTO, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its third quarter 2024 financial results after market close on Thursday, November 7, 2024. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in GlobeNewswire ? last month PROF -2.12% Profound Medical Appoints Tom Tamberrino as Chief Commercial Officer – Mr. Tamberrino and Profound’s CEO, Arun Menawat, previously worked together at NOVADAQ before it was acquired by Stryker in 2017 – – Appointment comes as Profound continues to make final preparations for the permanent CPT? Category 1 codes for TULSA going into effect at the beginning of 2025 – TORONTO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, i GlobeNewswire ? last month PROF -2.12% Owning 50% shares,institutional owners seem interested in Profound Medical Corp. (TSE:PRN), Key Insights Institutions' substantial holdings in Profound Medical implies that they have significant influence over... Simply Wall St. ? last month PROF -2.12% Profound Medical Corp (PROF) Q2 2024 Earnings Call Highlights: Strong Revenue Growth Amidst ... Profound Medical Corp (PROF) reports a 39% revenue increase in Q2 2024, driven by recurring sources, despite challenges in profitability and reimbursement transitions. GuruFocus.com ? last month PROF -2.12% iAccess Alpha's Buyside Best Ideas Virtual Fall Conference September 24-25, 2024 RALEIGH, NC / ACCESSWIRE / September 20, 2024 / iAccess Alpha's "Buyside Best Ideas Virtual Fall Conference" is taking place on September 24-25, 2024. The conference begins on Tuesday, September 24, with Company presentations beginning at 9:30 a.m. ... ACCESSWIRE ? last month LRHC ICAD PROF -2.12% Profound Medical’s PRO-Talk Live! Event Features the Present and Future of TULSA - Educational event for physicians by physicians; participants heard from an esteemed panel of experts, innovators, and guest speakers - - Global medtech leaders, Siemens Healthineers and Cook Medical, shared their common vision with Profound of creating a total diagnostic and interventional MR solution for prostate disease - TORONTO, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that deve GlobeNewswire ? 2 months ago PROF -2.12% The past three years for Profound Medical (TSE:PRN) investors has not been profitable In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market... Simply Wall St. ? 2 months ago PROF -2.12% Profound Medical to Participate in Lake Street’s Best Ideas Growth Conference TORONTO, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today that management will participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth “Big8” Conference on September 12, 2024 in New York City. The event will consist of one-on-one investor meetings. Due to th GlobeNewswire ? 2 months ago PROF -2.12% Rashed Dewan Bought 41% More Shares In Profound Medical Even if it's not a huge purchase, we think it was good to see that Rashed Dewan, the Chief Financial Officer of... Simply Wall St. ? 2 months ago PROF -2.12% Profound Medical Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag Profound Medical ( TSE:PRN ) Second Quarter 2024 Results Key Financial Results Net loss: US$6.92m (loss narrowed by... Simply Wall St. ? 3 months ago PROF -2.12% Profound Medical Announces Second Quarter 2024 Financial Results TORONTO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the second quarter ended June 30, 2024. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with International Financial Reporti GlobeNewswire ? 3 months ago PROF -2.12% Profound Medical to Release Second Quarter 2024 Financial Results on August 8 – Conference Call to Follow TORONTO, July 18, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its second quarter 2024 financial results after market close on Thursday, August 8, 2024. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in GlobeNewswire ? 3 months ago PROF -2.12% Profound Medical Announces Category 1 CPT Codes Proposed CY2025 Rule for TULSA to Treat Prostate Diseases TORONTO, July 11, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that U.S. Centers for Medicare and Medicaid Services (CMS) has issued its proposed rules establishing, for the first time, a Category 1 CPT code for the Transurethral Ultrasound Ablation (“TULSA”) procedure, effective Jan GlobeNewswire ? 4 months ago PROF -2.12% Insider Stock Buying Reaches US$781.1k On Profound Medical It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it... Simply Wall St. ? 5 months ago PROF -2.12% Profound Medical Annual General Meeting of Shareholders Voting Results TORONTO, May 15, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the voting results from its Annual General Meeting of Shareholders that was held today (the “Meeting”). A total of 15,336,388 common shares, representing 62.78% of the common shares outstanding, were represented in person and by proxy at the Meeting. All of the matters put forward before the shareholders, as set out in the Company’s management information GlobeNewswire ? 6 months ago PROF -2.12% Performance Overview Trailing total returns as of 11/18/2024, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index Return PROF S&P/TSX Composite index YTD -7.66% +19.17% 1-Year -26.45% +23.80% 3-Year -34.06% +15.35%
